Aims To characterize the relationship between blood pressure (BP) or heart rate and
mortality and morbidity in chronic obstructive pulmonary disease (COPD). Methods and …

Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of
mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only …

Chronic obstructive pulmonary disease (COPD) is а highly prevalent, complex and
heterogeneous clinical condition which is associated with significant concomitant diseases …

Importance There is concern that long-acting muscarinic antagonists increase
cardiovascular morbidity or mortality in patients with chronic obstructive pulmonary disease …

Rationale: There is uncertainty on the use of using triple therapy (inhaled
corticosteroids/long-acting β-agonist/long-acting muscarinic antagonist) inhaler therapy for …

Inhaled long-acting β-adrenergic agonists (LABAs) and short-acting β-adrenergic agonists
are approved for the treatment of obstructive lung disease via actions mediated by β 2 …

Rationale There are no validated measures of disease activity in COPD. Since “active”
disease is expected to have worse outcomes (eg mortality), we explored potential markers of …

Los modelos de atención sanitaria actuales descritos en GesEPOC indican la mejor manera
de hacer un diagnóstico correcto, la categorización de los pacientes, la adecuada selección …

Background Estimates for lung function decline in chronic obstructive pulmonary disease
(COPD) have differed by study setting and have not been described in a UK primary care …

The use of inhaled corticosteroids (ICS) in combination with inhaled bronchodilators for
patients with chronic obstructive pulmonary disease (COPD) is a common practice in …